Rentschler Bio enhances collaboration in Japan

Japan is the world's third largest pharmaceuticals market, which is forecast to reach $89 to $93 billion by 2023. The country is expected to continue dominating this corner of the global market.

Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals based in Germany, has reported that it will further enhance and develop the existing collaboration in Japan with Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary of Sumitomo Corporation.

Through strong collaboration with SPI, Rentschler Biopharma has secured new contracts with Japanese pharmaceutical companies.

Japan is one of the largest biopharmaceutical markets in the world and is an important area of growth for Rentschler Biopharma.

There are over 100 domestic pharmaceutical companies in Japan, with many of the mid-sized and larger-sized firms in recent years developing drug candidates with innovative and new modalities, such as biologics and gene and cell therapies, for markets worldwide. This is increasing the involvement of Japanese pharmaceutical companies in biopharmaceutical enterprises. Japan has also seen an increase in biopharmaceutical start-ups, which is further driving the industry's growth.

SPI and Rentschler Biopharma are working together with Japanese clients to outline projects from early clinical stage up to commercial launch and ensure optimal service.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.